Fulcrum Therapeutics (FULC) Competitors $2.92 +0.01 (+0.17%) As of 12:09 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock FULC vs. PRTA, REPL, ABUS, VECT, KALV, AVBP, TRVI, RCKT, PHAR, and ANABShould you be buying Fulcrum Therapeutics stock or one of its competitors? The main competitors of Fulcrum Therapeutics include Prothena (PRTA), Replimune Group (REPL), Arbutus Biopharma (ABUS), VectivBio (VECT), KalVista Pharmaceuticals (KALV), ArriVent BioPharma (AVBP), Trevi Therapeutics (TRVI), Rocket Pharmaceuticals (RCKT), Pharming Group (PHAR), and AnaptysBio (ANAB). These companies are all part of the "pharmaceutical products" industry. Fulcrum Therapeutics vs. Prothena Replimune Group Arbutus Biopharma VectivBio KalVista Pharmaceuticals ArriVent BioPharma Trevi Therapeutics Rocket Pharmaceuticals Pharming Group AnaptysBio Fulcrum Therapeutics (NASDAQ:FULC) and Prothena (NASDAQ:PRTA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their community ranking, analyst recommendations, dividends, institutional ownership, profitability, risk, media sentiment, valuation and earnings. Does the media prefer FULC or PRTA? In the previous week, Prothena had 4 more articles in the media than Fulcrum Therapeutics. MarketBeat recorded 8 mentions for Prothena and 4 mentions for Fulcrum Therapeutics. Prothena's average media sentiment score of 1.05 beat Fulcrum Therapeutics' score of 0.91 indicating that Prothena is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fulcrum Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Prothena 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, FULC or PRTA? Fulcrum Therapeutics has a beta of 2.13, indicating that its share price is 113% more volatile than the S&P 500. Comparatively, Prothena has a beta of 0.07, indicating that its share price is 93% less volatile than the S&P 500. Do analysts rate FULC or PRTA? Fulcrum Therapeutics currently has a consensus target price of $8.63, indicating a potential upside of 194.87%. Prothena has a consensus target price of $55.00, indicating a potential upside of 476.10%. Given Prothena's stronger consensus rating and higher possible upside, analysts plainly believe Prothena is more favorable than Fulcrum Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Fulcrum Therapeutics 1 Sell rating(s) 6 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.11Prothena 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.75 Does the MarketBeat Community prefer FULC or PRTA? Prothena received 514 more outperform votes than Fulcrum Therapeutics when rated by MarketBeat users. Likewise, 70.43% of users gave Prothena an outperform vote while only 60.87% of users gave Fulcrum Therapeutics an outperform vote. CompanyUnderperformOutperformFulcrum TherapeuticsOutperform Votes9860.87% Underperform Votes6339.13% ProthenaOutperform Votes61270.43% Underperform Votes25729.57% Which has better valuation & earnings, FULC or PRTA? Fulcrum Therapeutics has higher earnings, but lower revenue than Prothena. Fulcrum Therapeutics is trading at a lower price-to-earnings ratio than Prothena, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFulcrum Therapeutics$80M1.97-$97.33M-$0.22-13.30Prothena$135.16M3.80-$147.03M-$2.30-4.15 Is FULC or PRTA more profitable? Fulcrum Therapeutics has a net margin of 0.00% compared to Prothena's net margin of -90.50%. Fulcrum Therapeutics' return on equity of -7.31% beat Prothena's return on equity.Company Net Margins Return on Equity Return on Assets Fulcrum TherapeuticsN/A -7.31% -6.74% Prothena -90.50%-22.67%-19.68% Do institutionals and insiders believe in FULC or PRTA? 89.8% of Fulcrum Therapeutics shares are owned by institutional investors. Comparatively, 97.1% of Prothena shares are owned by institutional investors. 4.1% of Fulcrum Therapeutics shares are owned by company insiders. Comparatively, 28.2% of Prothena shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. SummaryProthena beats Fulcrum Therapeutics on 12 of the 18 factors compared between the two stocks. Remove Ads Get Fulcrum Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FULC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FULC vs. The Competition Export to ExcelMetricFulcrum TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$157.89M$6.34B$5.34B$7.60BDividend YieldN/A3.23%5.11%4.33%P/E Ratio-9.446.8321.7617.83Price / Sales1.97222.48378.0693.28Price / CashN/A65.6738.1534.64Price / Book0.775.836.414.00Net Income-$97.33M$141.86M$3.20B$247.23M7 Day Performance10.80%9.28%6.59%7.42%1 Month Performance-6.25%-12.40%-8.57%-6.15%1 Year Performance-60.26%-12.11%10.11%-0.03% Fulcrum Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FULCFulcrum Therapeutics2.3044 of 5 stars$2.93+0.2%$8.63+194.9%-61.1%$157.89M$80M-9.44100Short Interest ↓Positive NewsGap DownPRTAProthena3.5349 of 5 stars$10.84-0.2%$55.00+407.4%-55.3%$583.49M$135.16M-4.71130Positive NewsHigh Trading VolumeREPLReplimune Group3.5997 of 5 stars$7.49+0.4%$19.43+159.4%+5.2%$576.84MN/A-2.44210Positive NewsABUSArbutus Biopharma1.7383 of 5 stars$3.01-6.8%$5.50+82.7%+12.7%$576.36M$6.17M-7.0090Positive NewsVECTVectivBioN/A$16.85flatN/AN/A$573.24M$27.34M0.0030High Trading VolumeKALVKalVista Pharmaceuticals4.1832 of 5 stars$11.50+7.4%$24.83+115.9%+0.5%$571.73MN/A-3.16100Gap DownHigh Trading VolumeAVBPArriVent BioPharma1.1248 of 5 stars$16.61+1.2%$39.00+134.8%+8.9%$565.01MN/A-6.4640News CoveragePositive NewsGap DownTRVITrevi Therapeutics3.396 of 5 stars$5.78-4.5%$17.56+203.8%+103.8%$558.82MN/A-13.1420RCKTRocket Pharmaceuticals4.6314 of 5 stars$5.19+1.4%$43.00+728.5%-75.6%$553.41MN/A-1.89240Insider TradeNews CoveragePositive NewsGap UpHigh Trading VolumePHARPharming Group2.4383 of 5 stars$8.11+5.5%$30.00+269.9%-24.0%$551.73M$297.20M-31.19280Short Interest ↓Positive NewsANABAnaptysBio2.5273 of 5 stars$17.78-3.9%$35.11+97.5%-21.4%$545.26M$91.28M-2.92100Positive NewsGap Down Remove Ads Related Companies and Tools Related Companies PRTA Competitors REPL Competitors ABUS Competitors VECT Competitors KALV Competitors AVBP Competitors TRVI Competitors RCKT Competitors PHAR Competitors ANAB Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FULC) was last updated on 4/15/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon’s Silver Play? Trump Clears the PathNothing is confirmed—yet. But Musk has disrupted every industry he's touched, and Trump's policies make the ti...Priority Gold | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fulcrum Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Fulcrum Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy FULC Stock Free FULC Stock Alerts